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ORIGINAL ARTICLE MYCOLOGYDifferential association of ﬂuconazole dose and dose/MIC ratio with
mortality in patients with Candida albicans and non-albicans bloodstream
infectionT. Brosh-Nissimov1,2 and R. Ben-Ami1,2
1) Infectious Disease Unit, Tel-Aviv Sourasky Medical Center and 2) Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, IsraelAbstractTargeting ﬂuconazole therapy to achieve predeﬁned pharmacodynamic goals has been suggested as a means of optimizing the treatment of
patients with candidaemia. However, data regarding species-speciﬁc dosing targets are inconclusive. We retrospectively analysed a cohort of
75 adult patients with Candida bloodstream infection (BSI) who received initial treatment with ﬂuconazole for 48 h (36 Candida albicans and
39 non-albicans Candida (NAC)). Fluconazole dose, the dose/MIC ratio and the 24-h area under the concentration–time curve (AUC24)/MIC
ratio were determined for each patient, and classiﬁcation and regression tree analysis was used to determine breakpoints for signiﬁcant
interactions with 30-day survival. Both ﬂuconazole exposure parameters and patient-related and disease-related variables were assessed
in univariable and multivariable survival models. The crude 30-day mortality rate was 32% (44% and 21% for C. albicans and NAC,
respectively). An average ﬂuconazole dose of >200 mg/day, a dose/MIC ratio of >400 and an AUC24/MIC ratio of >400 were associated
with a higher 30-day survival rate and better microbiological response in patients with C. albicans BSI but not in those with NAC BSI.
Baseline chronic kidney disease was a risk factor for ﬂuconazole underdosing and mortality. Severity of sepsis (Sequential Organ Failure
Assessment score) was the only signiﬁcant predictor of death in patients with NAC BSI. We conclude that, although pharmacodynamic
target-directed ﬂuconazole dosing may help to optimize outcomes for patients with C. albicans BSI, additional studies are needed to
deﬁne the role of ﬂuconazole in the treatment of NAC BSI.
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E-mail: tbrosh@gmail.comIntroductionCandida species rank fourth among the causes of nosocomial
bloodstream infection (BSI), and are associated with the highest
mortality rate of all causative agents [1]. Fluconazole was
introduced as a treatment for candidiasis two decades ago, and
remains the most frequently prescribed drug for candidaemiaClinical Microbiology and Infection © 2015 European Society of C[2]. Although increasing rates of ﬂuconazole resistance among
some Candida species have led to the expanded use of echi-
nocandins as frontline treatment for candidaemia [3], ﬂucona-
zole is a viable treatment option for haemodynamically stable
patients with no history of recent azole exposure [4]. More-
over, emerging resistance to echinocandins, speciﬁcally in
Candida glabrata, suggests that overuse of these agents may
eventually lead to attrition of their potency [2,5–7]. Hence,
maximizing the effectiveness of ﬂuconazole for the treatment of
invasive candidiasis is an important goal.
Optimizing dosing regimens to achieve deﬁned pharmaco-
dynamic (PD) goals is a potential strategy to enhance the efﬁ-
cacy of ﬂuconazole treatment. Non-clinical studies have
determined that the 24-h area under the concentration–timeClin Microbiol Infect 2015; 21: 1011–1017
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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best with ﬂuconazole efﬁcacy [8,9]. Moreover, the linear cor-
relation between ﬂuconazole dose and the AUC24 allows the
dose to be used as a surrogate parameter in outcome studies
[8]. However, clinical studies have yielded conﬂicting results
regarding the optimal ﬂuconazole PD target for patients with
candidaemia [10–13]. We hypothesized that this inconsistency
may be due to Candida species-speciﬁc differences in response
to ﬂuconazole exposure. In the present study, we aimed to
assess the impact of ﬂuconazole exposure on the outcome of
BSIs caused by Candida albicans and non-albicans Candida (NAC)
species.Materials and methodsClinical data
We reviewed the records of the Tel Aviv Medical Center
clinical microbiology laboratory from 1 January 2007 to 31
December 2013, and identiﬁed patients with Candida species
BSI. Patients with at least one peripheral blood specimen
growing Candida species were included in this study if they
were aged 18 years and had received initial monotherapy with
ﬂuconazole for 48 h. Patients with Candida krusei infection
were excluded. The study was approved by the Tel Aviv
Medical Center institutional review board.
Data were extracted from patient charts by the use of stan-
dardized data collection forms. The source of candidaemia was
determined according to the clinical diagnosis of the treating
physicians and the infectious disease consultant, and was
retrospectively reviewed by the authors. Severity of illness on
the ﬁrst day of candidaemia was recorded with the Sequential
Organ Failure Assessment (SOFA) score [14]. Hypotension was
deﬁned as a systolic blood pressure of <90 mmHg, an acute
decrease in systolic or diastolic blood pressure of30 mmHg or
20 mmHg, respectively, or the need for vasopressors. The
time to initiation of ﬂuconazole treatment was deﬁned as the
time in days from the ﬁrst positive blood culture to treatment
initiation. Neutropenia was deﬁned as an absolute neutrophil
count of <500 cells/μL. Baseline renal function was estimated
with the Modiﬁcation of Diet in Renal Disease glomerular
ﬁltration rate equation [15]. Chronic kidney disease was deﬁned
as a glomerular ﬁltration rate of <50 mL/min. The primary
outcome measure was death occurring up to 30 days after the
ﬁrst day of candidaemia. Early response, deﬁned as being alive
and free of candidaemia on day 7, was a secondary endpoint.
Microbiological analyses
Blood samples were inoculated into aerobic culture bottles, and
growth was detected with the BacT/Alert automated bloodClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectculture system (bioMerieux, Marcy l’Etoile, France). Candida
species were identiﬁed according to growth characteristics on
CHROMagar (Hardy Laboratories, Santa Monica, CA, USA) and
the Vitek 2 system with the YST-ID card (bioMerieux). Flu-
conazole susceptibility was determined with Etest strips (bio-
Merieux), according to the manufacturer’s instructions. Results
were read after 24 h, or after 48 h if insufﬁcient growth was
present at 24 h. Isolates were classiﬁed as susceptible, sus-
ceptible dose-dependent (S-DD) or resistant by use of the
revised CLSI MIC susceptibility breakpoints [8].
Fluconazole exposure parameters
We assessed three ﬂuconazole exposure parameters for their
interaction with 30-day survival and early response: ﬂucona-
zole dose, the dose/MIC ratio, and the AUC24/MIC ratio. To
account for day-to-day ﬂuconazole dose variations, dose was
calculated in two ways: from the ﬂuconazole maintenance
dose started on the second day of treatment, and from the
average daily dose over the ﬁrst 3 days of treatment. Because
similar associations with patient outcomes were obtained with
both calculations, the results of analyses based on the average
ﬂuconazole dose are reported. Fluconazole clearance was
calculated with a previously published equation that models
ﬂuconazole clearance as a function of creatinine clearance
[16]. AUC24 was calculated by dividing the ﬂuconazole daily
dose by ﬂuconazole clearance. Classiﬁcation and regression
tree (CART) analysis was used to detect signiﬁcant ﬂuconazole
exposure breakpoints associated with 30-day survival. For
each parameter, CART analysis was performed for the entire
cohort and separately for patients with C. albicans BSI and
NAC BSI.
Analysis of factors associated with clinical outcomes
Patient variables (age, sex, comorbidity, SOFA score, neu-
tropenia, and baseline renal function), microbiological variables
(Candida species and ﬂuconazole MIC) and treatment param-
eters (ﬂuconazole exposure, time to initiation of ﬂuconazole,
and removal of a central venous catheter (CVC)) were
assessed for their effects on crude 30-day mortality. Survival
was determined with the Kaplan–Meier method, and individual
variables were assessed with the log-rank test. Variables asso-
ciated with an effect on survival rate at an α-level of <0.1 were
ﬁtted into a Cox proportional hazards model. Fluconazole
exposure parameters were entered separately into the model
to assess their effects. Similarly, the SOFA score and hypo-
tension were entered separately into the model, owing to
overlap between these variables. A type I error of <0.05 was
considered to be statistically signiﬁcant. All calculations were
performed with Stata 11.2 (StataCorp, College Station, TX,
USA).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
TABLE 2. Fluconazole susceptibility of 75 Candida isolates













C. albicans 36 (48) 34 (94) 0 (0) 2 (6) 0.5 (0.064–512)
Non-albicans
species
39 (52) 27 (69) 11 (28) 1 (3) 0.5 (0.25–128)
C. tropicalis 17 (23) 17 (100) 0 (0) 0 (0) 0.5 (0.38–2)
C. parapsilosis 13 (17) 10 (76.9) 2 (15) 1 (7.6) 0.5 (0.25–128)
C. glabrata 8 (11%) NA 8 (100) 0 (0) 5 (2–32)
C. guilliermondii 1 (1) 0 1 (100) 0 4
Total 75 (100) 61 (81.3) 11 (14.6) 3 (4) 0.5 (0.064–512)
NA, not applicable; R, resistant; S, susceptible; S-DD, susceptible dose-dependent.
aFluconazole susceptibility breakpoints were those deﬁned by the revised CLSI
criteria [8], as follows. C. albicans, C. tropicalis, and C. parapsilosis: S, MIC of 2 mg/L;
S-DD, MIC of >2 mg/L and 4 mg/L; R, MIC of >4 mg/L. C. glabrata: S-DD, MIC of
32 mg/L, R, MIC of >32 mg/L. Although no formal susceptibility breakpoint has
been set for C. guilliermondii, we considered the single isolate in this study to be S-
DD (MIC of 4 mg/L).Seventy-ﬁve episodes of Candida BSI in 75 patients were
included in the analysis. Demographic and clinical characteris-
tics are shown in Table 1. Most patients (61%) had a CVC at the
time of candidaemia, and CVC infection was the most common
source of candidaemia (56%). Five patients (7%) were neu-
tropenic. Thirty-two per cent of patients were hypotensive at
presentation. C. albicans constituted 48% of bloodstream iso-
lates. Three isolates (4%) were resistant to ﬂuconazole, i.e. two
C. albicans isolates (6%) and one Candida parapsilosis isolate; and
11 isolates (14.6%) were S-DD, i.e. eight C. glabrata isolates
(100%) and two C. parapsilosis isolates (15%) (Table 2).
The ﬂuconazole dose was 600–800 mg/day for six patients
(8.0%), 400 mg/day for 47 patients (62.6%), 300 mg/day for
three patients (4.0%), 200 mg/day for 18 patients (24.0%), and
100 mg/day for one patient. The variation in doses over the
initial 3 days of treatment was minor (coefﬁcient of variation,TABLE 1. Demographic and clinical characteristics of 75
patients with candidaemia
Characteristic Value
Age (years), median (IQR) 67 (24–100)
Sex (male/female), n 41/34 (54.6/45.3)
Department, n (%)
Internal medicine 38 (50.6)




Charlson Comorbidity Index, median (IQR) 2 (1–5)
ICU stay in the previous 30 days, n (%) 19 (25.3)
Cancer, n (%) 36 (48.0)
Solid organ 30 (40.0)
Haematological 6 (8.0)
Solid organ transplantation, n (%) 1 (1.3)
Stem cell transplantation, n (%) 1 (1.3)
Diabetes mellitus, n (%) 24 (32)
Chronic renal failure (Cr > 3 mg/dL), n (%) 20 (26.6)
Haemodialysis, n (%) 9 (12.0)
Cerebrovascular disease, n (%) 14 (18.6)
Previous myocardial infarction, n (%) 12 (16.0)
Dementia, n (%) 9 (12.0)
Congestive heart failure, n (%) 8 (10.6)
Chemotherapy within 30 days, n (%) 11 (14.6)
Corticosteroids within 30 days, n (%) 11 (14.6)
Neutropenia, n (%) 5 (6.6)
Mechanical ventilation, n (%) 19 (25.3)
TPN, n (%) 12 (16.0)
CVC present, n (%) 46 (61.3)
Any surgery within 30 days, n (%) 28 (37.3)
Abdominal surgery 15 (20.0)
Urological surgery 4 (5.3)
Orthopaedic surgery 4 (5.3)
Other 5 (6.6)
Source of candidaemia, n (%)
CVC infection 42 (56.0)
Primary candidaemia 14 (18.6)
Urinary tract infection 12 (16.0)
Peritonitis and abdominal abscess 9 (12.0)
Cholangitis 6 (8.0)
Other 3 (4.0)
Hypotension, n (%) 24 (32.0)
SOFA score, median (IQR) 4 (2–7)
Pitt bacteraemia score, median (IQR) 2 (0–3)
Cr, creatinine; CVC, central venous catheter; ICU, intensive-care unit; IQR,
interquartile range; SOFA, Sequential Organ Failure Assessment; TPN, total
parenteral nutrition.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology an1.8%). Eighteen of 19 (94.7%) patients treated with a ﬂucona-
zole dose of 100–200 mg/day had chronic kidney disease vs. 13
of 56 (23.2%) patients treated with >200 mg/day (p < 0.001).
Average ﬂuconazole doses were similar in C. albicans and NAC
BSIs. Fluconazole dose/MIC and AUC24/MIC ratios were
signiﬁcantly higher for C. albicans BSI than for NAC BSI
(p < 0.001; Table 3).
Factors associated with 30-day mortality
Twenty-four patients (32%) died within 30 days of onset of
candidaemia. The mortality rates were 44% and 21% for
C. albicans BSI and NAC BSI, respectively (p 0.018). There was
only one case of metastatic infection of the spleen, and there
were no recorded relapses after treatment discontinuation.
For the entire cohort, CART analysis identiﬁed a ﬂuconazole
dose of 200 mg/day as being signiﬁcantly associated with 30-
day mortality, whereas no breakpoint was identiﬁed for dose/
MIC and AUC24/MIC ratios. Separate CART analyses of
C. albicans BSI and NAC BSI showed that signiﬁcantly decreased
mortality was associated with a ﬂuconazole dose of >200 mg/
day and a dose/MIC ratio of >400 in patients with C. albicans BSI
but not in those with NAC BSI (Table 4; Fig. 1).
Other cofactors that were signiﬁcantly associated with death
were mechanical ventilation, chronic kidney disease, hypoten-
sion on the ﬁrst day of candidaemia, and a SOFA score of >8
(Table 4).
For C. albicans BSI, resistance to ﬂuconazole (MIC of 4 mg/
L), a ﬂuconazole dose of 200 mg/day, a ﬂuconazole dose/MIC
ratio of 400, an AUC24/MIC ratio of 400 and chronic kidney
disease were associated with 30-day mortality (Table 4). For
NAC BSI, a SOFA score of >8 was the only variable that was
signiﬁcantly associated with 30-day mortality, whereas ﬂucon-
azole exposure parameters were not associated with statisti-
cally signiﬁcant differences in mortality (Table 4). A similar
association of ﬂuconazole exposure parameters with earlyd Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
TABLE 3. Association of Candida species and chronic kidney disease (CKD) with ﬂuconazole pharmacokinetics
Variable All episodes (N [ 75) C. albicans (N [ 36) NAC (N [ 39) p CKD (N [ 31) No CKD (N [ 44) p
FLC dose (mg), mean ± SD 372 ± 120 367 ± 126 376 ± 116 0.62 309 ± 149 415 ± 68 <0.0001
MIC50 (mg/L) 0.5 0.5 0.5 0.5 0.5
MIC90 (mg/L) 4 0.75 16 0.0001 16 4 0.52
FLC dose/MIC ratio, median (IQR) 800 (400–1066) 1052 (800–2105) 400 (100–800) <0.0001 533 (100–1052) 800 (666–1333) 0.10
GFR (mL/min), median (IQR) 58.0 (23.0–89.0) 56.2 (21.9–89.9) 58.7 (23.6–85.3) 0.8 19.4 (11.4–31.7) 83.8 (68.5–109.4) <0.0001
FLC clearance (mL/min/kg), median (IQR) 0.24 (0.13–0.33) 0.23 (0.13–0.33) 0.24 (0.13–0.32) 0.8 0.12 (0.10–0.16) 0.31 (0.27–0.39) <0.0001
AUC24/MIC ratio, median (IQR) 2895 (1106–4665) 3954 (2171–9687) 2206 (515–3163) 0.0001 3841 (867–9520) 2400 (1660–3253) 0.050
AUC24, 24-h area under the concentration–time curve; FLC, ﬂuconazole; GFR, glomerular ﬁltration rate; IQR, interquartile range; NAC, non-albicans Candida; SD, standard
deviation.
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C. albicans BSI (Fig. 2).
Univariate predictors of death were ﬁtted into a Cox pro-
portional hazards model, in which ﬂuconazole dose and chronic
kidney disease were treated as interacting covariates. For all
patients with candidaemia, a high SOFA score (>8) and a ﬂu-
conazole dose of 200 mg/day were signiﬁcant predictors of
30-day mortality (respectively: hazard ratio (HR) 3.87, 95% CI
1.65–9.05, p 0.002; and HR 3.25, 95% CI 1.28–8.27, p 0.013).
For patients with NAC BSI, a SOFA score of >8 was the only
signiﬁcant predictor of death (HR 11.2, 95% CI 2.6–48.1, p
0.001). For C. albicans BSI, A ﬂuconazole dose of 200 mg/day,
a dose/MIC ratio of 400 and an AUC24/MIC ratio of 400
were signiﬁcantly associated with 30-day mortality (respec-
tively: HR 4.7, 95% CI 1.45–15.4, p 0.010; HR 9.72, 95% CI
1.75–54.0, p 0.009; and HR 7.94, 95% CI 1.09–57.7, p 0.04;
Fig. 3). The SOFA score was forced into the Cox regression
model, but was not signiﬁcantly associated with death in pa-
tients with C. albicans BSI.
Finally, we analysed the association of ﬂuconazole AUC24/
MIC breakpoints described in previous studies with death. In
univariate analyses, AUC24/MIC breakpoints of 50 [11] and
100 [12] were both associated with mortality in patients with
C. albicans BSI (p 0.0003), but not in those with NAC BSI (pTABLE 4. Univariate analysis for factors affecting the 30-day morta
Variable
All episodes (n [ 75)
HR (95% CI) p
Age >65 years 1.7 (0.7–4.1) 0.21
Surgery in past 30 days 0.7 (0.3–1.8) 0.57
Presence of CVC 1.0 (0.4–2.4) 0.88
Corticosteroid use in past 30 days 0.8 (0.2–2.8) 0.79
Mechanical ventilation in past 30 days 2.6 (1.1–5.8) 0.021
Hypotension 2.2 (1.0-4.9) 0.05
SOFA score of >8 4.5 (1.9–10.4) <0.0001
Treatment delay of >2 days 0.9 (0.3–2.2) 0.85
Extraction of CVC 1.0 (0.4–2.3) 0.86
Fluconazole MIC of 4 mg/L 0.7 (0.2–2.5) 0.64
Fluconazole dose of 200 mg/day 3.39 (1.48–7.79) 0.004
Fluconazole dose/MIC ratio of 400 1.1 (0.4–2.6) 0.79
Fluconazole AUC24/MIC ratio of 400 0.97 (0.28–3.2) 0.96
Chronic kidney disease 2.4 (1.07–5.4) 0.02
Items in bold type were included in the multivariate analysis.
AUC24, 24-h area under the concentration–time curve; CVC, central venous catheter; HR,
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect0.6). However, neither of these breakpoints remained signiﬁ-
cantly associated with death when ﬁtted into the Cox regres-
sion model.DiscussionFluconazole remains an important drug for the treatment of
candidaemia, owing to its overall efﬁcacy, excellent safety
proﬁle, highly bioavailable oral formulation, linear pharmaco-
kinetics, good penetration into tissues, and low cost [4,8].
Deﬁning the optimal dosing of ﬂuconazole on the basis of PD
endpoints has been a goal of several studies, but the results
have varied signiﬁcantly [8,10–13,17–19]. Here, we show that
ﬂuconazole dose and the dose/MIC ratio are important pre-
dictors of the treatment response of patients with C. albicans
BSI. In contrast, we found no effect of ﬂuconazole exposure on
the survival of patients with NAC BSI, in whom the severity of
sepsis was the only signiﬁcant predictor of survival.
A ﬂuconazole dose/MIC ratio of 400 was associated with a
signiﬁcantly higher mortality rate in patients with C. albicans BSI.
The median ﬂuconazole MIC for C. albicans isolates in our study
was 0.5 mg/L (interquartile range, 0.19–0.5 mg/L). Thus, a daily
ﬂuconazole dose of 400 mg/day was sufﬁcient to surpass the PDlity rate
Candida albicans (n [ 36) Non-albicans Candida (n [ 39)
HR (95% CI) p HR (95% CI) p
1.9 (0.6–5.5) 0.22 1.8 (0.3–8.9) 0.46
1.1 (0.4–3.1) 0.73 0.2 (0.02–1.8) 0.16
0.7 (0.2–2.1) 0.62 2.0 (0.4–10.1) 0.38
0.5 (0.1–2.6) 0.49 1.2 (0.1–10.3) 0.82
2.4 (0.8–6.5) 0.08 2.5 (0.6–10.6) 0.20
1.6 (0.6–4.3) 0.33 2.4 (0.5–10.3) 0.21
2.3 (0.8–6.8) 0.11 12.4 (3.0–51.4) <0.0001
0.8 (0.3–2.4) 0.79 0.4 (0.05–3.7) 0.47
0.8 (0.3–2.3) 0.79 1.4 (0.3–5.6) 0.63
11.4 (2.0–63.7) 0.005 0.3 (0.04–3.1) 0.37
3.91 (1.39–11.02) 0.004 3.06 (0.7–12.8) 0.12
17.2 (3.7–79.8) <0.0001 0.9 (0.2–3.7) 0.91
11.4 (2.0–63.7) 0.005 0.52 (0.06–4.2) 0.54
3.05 (1.1–8.4) 0.03 1.6 (0.4–6.5) 0.48
hazard ratio; SOFA, Sequential Organ Failure Assessment.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
FIG. 1. Survival rate as a function of ﬂuconazole dose/MIC ratio. (a, b) Survival rates for a range of ﬂuconazole dose/MIC ratios: (a) Candida albicans
bloodstream infection; (b) non-albicans Candida bloodstream infection. (c) Number of Candida isolates by species in each ﬂuconazole dose/MIC range.
CMI Brosh-Nissimov and Ben-Ami Differential association of ﬂuconazole dose and dose/MIC 1015goal for 94% (34/36) of patients with C. albicans candidaemia.
Underdosing of ﬂuconazole was strongly associated with
chronic kidney disease, suggesting that the current recom-
mendation to halve the dose in patients with a creatinine
clearance of 50 mL/min may result in insufﬁcient ﬂuconazole
exposure in critically ill patients [20].
The reasons for the divergent inﬂuence of ﬂuconazole
pharmacodynamics on treatment outcomes for C. albicans and
NAC candidaemia are unclear, but some hypotheses may be
suggested. As is now recognized by both the EUCAST and the
CLSI, ﬂuconazole MICs cannot be uniformly applied across
different Candida species [8]. Signiﬁcantly, C. glabrata is inher-
ently non-susceptible to ﬂuconazole, a fact that has driven a
recommendation by the CLSI to treat even apparently sus-
ceptible isolates as S-DD [8], whereas the EUCAST has avoided
assigning a C. glabrata ﬂuconazole breakpoint altogether [21,22].
Unfortunately, the size of our study cohort precludes mean-
ingful assessment of treatment response for individual NACFIG. 2. Association of ﬂuconazole pharmacodynamic parameters with early t
MIC ratio and (c) 24-h area under the concentration–time curve (AUC24)/MIC
from blood and survival to day 7 from the onset of candidaemia. NAC, non-
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anspecies. Second, the ﬂuconazole MICs of some NAC species
are signiﬁcantly higher than those of C. albicans; thus, even if the
same PD goals apply to NAC species, attaining these goals may
be impractical. For example, the eight C. glabrata isolates in our
study had a median ﬂuconazole MIC of 5 mg/L (interquartile
range, 4–16 mg/L). Hence, a daily ﬂuconazole dose of 6.4 g
would be needed to ensure a dose/MIC ratio of >400 in at least
75% of patients with C. glabrata infection.
Finally, host factors may also be responsible for some of the
discrepancy. Patients with C. albicans BSI had signiﬁcantly more
severe illness than those with NAC BSI. Speciﬁcally, the prev-
alence of hypotension, mean SOFA scores and crude mortality
rates were signiﬁcantly higher for C. albicans BSI. Severity of
illness may be an important modiﬁer of the response to drug
dosing. Indeed, in the present study, patients with hypotension
and a SOFA score of >8 had a lower mortality rate if the dose/
MIC ratio exceeded 400 (p 0.058), whereas the mortality rate
of less ill patients was not affected by PD goal attainment.reatment outcome. Interaction between (a) ﬂuconazole dose, (b) dose/
ratio and early response to treatment, deﬁned as clearance of Candida
albicans Candida.
d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
FIG. 3. Multivariate analysis of risk factors for 30-day mortality. Hazard ratios (circles) and 95% CIs (whiskers) are shown for variables assessed for
their effects on 30-day mortality. (a) All episodes of candidaemia. (b) Candida albicans bloodstream infection. (C) Non-albicans Candida bloodstream
infection. AUC24, 24-h area under the concentration–time curve; SOFA, Sequential Organ Failure Assessment.
1016 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIData from animal models of invasive candidiasis have iden-
tiﬁed a ﬂuconazole AUC/MIC value of >50 as being predictive
of cure [23,24]. However, clinical studies have yielded various
breakpoints for ﬂuconazole doses associated with treatment
outcome in patients with candidiasis. Baddley et al. showed a
survival advantage at 6 weeks for patients treated with a dose/
MIC ratio of >11.5 (74% vs. 42.5%) [10]. Similarly to our study,
Pai et al. found that the in-hospital mortality rate was lowest for
patients in whom a ﬂuconazole dose/MIC ratio of >500 was
achieved [13]. Rodriguez-Tudela et al. reported that the rate of
clinical failure increased in patients with candidaemia when the
ﬂuconazole dose/MIC ratio fell below 100. It should be noted,
however, that of 126 patients in that study, only seven had
dose/MIC ratios between 100 and 400, whereas 102 had a ratio
of >400. Treatment success rates were 92% and 50% for pa-
tients with dose/MIC ratios of >400 and <100, respectively
[12]. Clancy et al. reported that a dose/MIC ratio of >50 was
associated with eradication of Candida from the bloodstream
[11]. It is of note that a high proportion of the patients (17/32)
were neutropenic. In a retrospective study by Eschenauer et al.
of 127 patients with C. glabrata BSI, a clinical response at day 14
occurred in 49% of patients with a dose/MIC ratio of >12.5 and
in only 20% of those with a lower dose/MIC ratio [19]. MICs
were determined with CLSI methods [10,11,13], EUCAST
methods [12], and unspeciﬁed methods [19]. C. krusei was not
excluded from these studies, and was associated with low dose/
MIC ratios and treatment failure [10,11]. Moreover, renal dis-
ease was not reported in most studies, and was not assessed as
a predictor of treatment outcome. In sum, the differences in
patient cohorts, clinical endpoints and microbiologicalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdeﬁnitions do not allow a single target ﬂuconazole dosing
metric to be deduced from these studies.
Our study is limited by its single-centre, retrospective design
and limited size. The patient population was heterogeneous and
representative of the general internal medicine and surgical
patient population.
In summary, we describe a species-dependent interaction
between ﬂuconazole exposure metrics and treatment out-
comes in patients with candidaemia. In patients with C. albicans
BSI, a ﬂuconazole dose of >200 mg/day and a ﬂuconazole dose/
MIC ratio of >400 were independently associated with survival.
In contrast, we found no ﬂuconazole exposure breakpoint that
was associated with improved survival in patients with NAC
BSI. If conﬁrmed in larger datasets, these results lend support to
the notion that PD principles can be used to guide ﬂuconazole
treatment in patients with C. albicans infection. However, given
the increasing proportion of Candida BSI caused by NAC spe-
cies, more detailed analysis of species-speciﬁc PD goals is
needed.Transparency declarationThe authors report no conﬂict of interests.References[1] Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond MB. Nosocomial bloodstream infections in US hospitals:ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
CMI Brosh-Nissimov and Ben-Ami Differential association of ﬂuconazole dose and dose/MIC 1017analysis of 24,179 cases from a prospective nationwide surveillance
study. Clin Infect Dis 2004;39(3):309–17.
[2] Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche H-U,
Quan S-P, et al. Epidemiology and outcomes of candidemia in 3648
patients: data from the Prospective Antifungal Therapy (PATH Alli-
ance®) registry, 2004–2008. Diagn Microbiol Infect Dis 2012;74(4):
323–31.
[3] Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ,
Lortholary O, et al. ESCMID guideline for the diagnosis and manage-
ment of Candida diseases 2012: non-neutropenic adult patients. Clin
Microbiol Infect 2012;18(s7):19–37.
[4] Pappas PG, Kauffman CA, Andes D, Benjamin J, Calandra TF,
Edwards JJE, et al. Clinical practice guidelines for the management of
candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis 2009;48(5):503–35.
[5] Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C,
Catania J, Booker R, et al. Increasing echinocandin resistance in Candida
glabrata: clinical failure correlates with presence of FKS mutations and
elevated minimum inhibitory concentrations. Clin Infect Dis
2013;56(12):1724–32.
[6] Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M,
Dromer F, Guillemot D, et al. Prior caspofungin exposure in patients
with hematological malignancies is a risk factor for subsequent funge-
mia due to decreased susceptibility in Candida spp.: a case–control
study in Paris, France. Antimicrob Agents Chemother 2011;55(11):
5358–61.
[7] Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-suscep-
tible Candida isolates in cancer patients. J Antimicrob Chemother 2010
Feb;65(2):293–5.
[8] Pfaller MA, Andes D, Deikema DJ, Espinel-Ingroff D, Sheehan D. Wild-
type MIC distributions, epidemiological cutoff values and species-
speciﬁc clinical breakpoints for ﬂuconazole and Candida: time for
harmonization of CLSI and EUCAST broth microdilution methods.
Drug Resist Updat 2010;13(6):180–95.
[9] Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J,
Roberts JA. Pharmacokinetic evaluation of ﬂuconazole in critically
ill patients. Expert Opin Drug Metab Toxicol 2011;7(11):
1431–40.
[10] Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association
of ﬂuconazole pharmacodynamics with mortality in patients with
candidemia. Antimicrob Agents Chemother 2008;52(9):3022–8.
[11] Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole
MIC and the ﬂuconazole dose/MIC ratio correlate with therapeutic
response among patients with candidemia. Antimicrob Agents Che-
mother 2005;49(8):3171–7.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology an[12] Rodríguez-Tudela JL, Almirante B, Rodríguez-Pardo D, Laguna F,
Donnelly JP, Mouton JW, et al. Correlation of the MIC and dose/MIC
ratio of ﬂuconazole to the therapeutic response of patients with
mucosal candidiasis and candidemia. Antimicrob Agents Chemother
2007;51(10):3599–604.
[13] Pai MP, Turpin RS, Garey KW. Association of ﬂuconazole area under
the concentration–time curve/MIC and dose/MIC ratios with mortality
in nonneutropenic patients with candidemia. Antimicrob Agents
Chemother 2007;51(1):35–9.
[14] Ferreira FL, Bota DP, Bross A, Melot C, Vincent J-L. Serial evaluation
of the SOFA Score. JAMA 2001;286(14):1754–8.
[15] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AFI, Feldman HI,
et al. A new equation to estimate glomerular ﬁltration rate. Ann Intern
Med 2009;150(9):604–12.
[16] Sobue S, Tan K, Layton G, Leclerc V, Weil A. The effects of renal
impairment on the pharmacokinetics and safety of fosﬂuconazole and
ﬂuconazole following a single intravenous bolus injection of fos-
ﬂuconazole. Br J Clin Pharmacol 2004;57(6):773–84.
[17] Rex JH, Pfaller M, Walsh TJ, Chaturvedi V, Espinel-Ingroff D,
Ghannoum M, et al. Antifungal susceptibility testing: practical aspects
and current challenges. Clin Microbiol Rev 2001;14(4):643–58.
[18] Cuesta I, Bielza C, Larrañaga P, Cuenca-Estrella M, Laguna F, Rodri-
guez-Pardo D, et al. Data mining validation of ﬂuconazole breakpoints
established by the European Committee on Antimicrobial Suscepti-
bility Testing. Antimicrob Agents Chemother 2009;53(7):2949–54.
[19] Eschenauer GA, Carver PL, Lin S-W, Klinker KP, Chen Y-C,
Potoski BA, et al. Fluconazole versus an echinocandin for Candida
glabrata fungaemia: a retrospective cohort study. J Antimicrob Che-
mother 2013;68(4):922–6.
[20] Pﬁzer. Fluconazole (Diﬂucan)—prescribing information. 2013. Avail-
able at: http://labeling.pﬁzer.com/ShowLabeling.aspx?id=575#Dosage.
[21] Rodriguez-Tudela JL, Donnelly M, Arendrup MC, Arikan S, Barchiesi F,
Bille J, et al. EUCAST technical report on ﬂuconazole. Clin Microb
Infect 2008;14(2):193–5.
[22] EUCAST. Clinical breakpoints— fungi (v. 6.1). European Society of
clinical microbiology and infectious diseases. 2013. Available at: http://
www.eucast.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/AFST/
Antifungal_breakpoints_v_7.0.pdf.
[23] Andes D, van Ogtrop M. Characterization and quantitation of the
pharmacodynamics of ﬂuconazole in a neutropenic murine dissemi-
nated candidiasis infection model. Antimicrob Agents Chemother
1999;43(9):2116–20.
[24] Louie A, Drusano GL, Banerjee P, Liu Q-F, Liu W, Kaw P, et al.
Pharmacodynamics of ﬂuconazole in a murine model of systemic
candidiasis. Antimicrob Agents Chemother 1998;42(5):1105–9.d Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1011–1017
